Loading provider…
Loading provider…
Hematology & Oncology Physician in Los Angeles, CA
NPI: 1730109331Primary Employer
UCLA Medical Plaza
uclahealth.org
HQ Phone
Get MD Antoni's Phone Numberphone_androidMobile
Get MD Antoni's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2001 - 2027
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Hematology and Medical Oncology
1998 - 2001
Universidad de Barcelona Faculty of Medicine
Medical School
Until 1990
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 61 | 156 |
| 2 | J7050Infusion, normal saline solution , 250 cc | 34 | 115 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 32 | 46 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 30 | 66 |
| 5 | 96413Infusion of chemotherapy into a vein up to 1 hour | 27 | 96 |
Authors: Michael Postow, Philip Wong, Jedd Wolchok, Philip Wong
Journal: Cell Res
Publication Date: 2015-01-13
Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development.
Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells
Authors: John Glaspy
Publication Date: 2004-04
Lead Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: Bristol-Myers Squibb, Array BioPharma
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, DRUG: Binimetinib
Lead Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: California Institute for Regenerative Medicine (CIRM), City of Hope National Medical Center, Parker Institute for Cancer Immunotherapy, Melanoma Research Alliance
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Fludeoxyglucose F-18, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, DRUG: Cyclophosphamide, DRUG: Fludarabine Phosphate, PROCEDURE: Computed Tomography, PROCEDURE: Biopsy, BIOLOGICAL: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Lead Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: GlaxoSmithKline, Tesaro, Inc.
Intervention / Treatment: DRUG: [18F] CFA